Startup Of The Week: PredicTx Health
PredicTx Health is a spin-out from the University of Melbourne utilizing AI, body composition analysis, and 3D imaging to tailor chemotherapy treatments. Traditional chemotherapy often results in incorrect dosing for over 80% of cancer patients due to…
PredicTx Health is a spin-out from the University of Melbourne utilizing AI, body composition analysis, and 3D imaging to tailor chemotherapy treatments. Traditional chemotherapy often results in incorrect dosing for over 80% of cancer patients due to neglect of personal factors. The platform developed by PredicTx Health calculates patient-specific doses, enhancing clinical outcomes.
PredicTx Health is a precision oncology startup from the University of Melbourne, founded by Professor Justin Yeung and Abhijeet Waykar. The company has developed an AI tool that personalizes chemotherapy dosing using CT scan data, moving away from the conventional body surface area-based approach.
By analyzing factors such as fat, muscle, and metabolism, PredicTx Health provides more accurate chemotherapy dosages. Supported by six years of research, the company has raised a $1.6 million pre-seed round for deployment and testing in hospitals across Australia and India, with plans for international expansion.
PredicTx Health leverages AI and 3D body scans to personalize chemotherapy dosing more accurately. This involves analyzing muscle, fat, bone, and tumor volume, beyond just height and weight, to predict patient reactions to treatment. This approach aims to reduce toxicities associated with incorrect dosing, an issue affecting over 60% of colorectal cancer patients.
PredicTx Health is a spin-out from the University of Melbourne utilizing AI, body composition analysis, and 3D imaging to tailor chemotherapy treatments.
Backed by top surgical academics and digital health experts, PredicTx Health has demonstrated clinical benefits in tests conducted at Western Health.
Market for AI-Powered Precision Oncology
With an annual diagnosis of 20 million new cancer cases worldwide, there is a growing demand for personalized medicine. Current chemotherapy dosing methods, which consider only height and weight, do not account for crucial factors like muscle, bone, and fat that affect drug metabolism.
PredicTx Health addresses this issue by using AI and CT scan data to predict the right dosage for each individual, aiming to reduce toxicities and improve treatment success rates. As cancer cases rise, the demand for precision oncology continues to increase.
PredicTx Health is partnering with hospitals, cancer centers, and research labs in Australia and India. Initial clinical trials are underway at Western Health. More information can be found at PredicTx.com .
Based on reporting by techround.co.uk.
